Abstract
Gout is the most common form of inflammatory arthritis worldwide. The cardinal clinical manifestations are gout flares and subcutaneous tophi, which both cause significant pain, disability, reduction in quality of life, and contribute to hospital admissions. A sustained reduction in serum urate of less than 0·36 mmol/L has been shown, with time, to lead to a reduction and cessation of flares and resorption of tophi,1 and this treat-to target urate approach is recommended by rheumatology societies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
